Table 2 Baseline Characteristics and pCR Rates of the SpheroNEO cohort

Characteristics

%

n

%

n

%

P

All Patients

78

100

22

28.2

56

71.8

Age at diagnosis, years

.207

  ≤50

43

55.1

15

34.9

28

65.1

  >50

35

44.9

7

20.0

28

80.0

Mean

.029

Range

Tumor stage

.779

  cT1/T2

56

72.7

16

28.6

40

71.4

  cT3/4

21

27.3

5

23.8

16

76.2

  Not documented

1

-

Nodal status

1.000

  cN+

42

54.5

12

28.6

30

71.4

  cN-

35

45.5

10

28.6

25

71.4

  Not documented

1

-

Grading

.123

  G1/2

41

53.9

8

19.5

33

80.5

  G3

35

46.1

13

37.1

22

62.9

  Not documented

2

-

Histologic type

.449

  Invasive ductal/other

70

89.7

21

30.0

49

70.0

  Invasive lobular

8

10.0

1

12.5

7

87.5

HR status

.001

  ER+/PR+

39

52.0

4

10.3

35

89.7

  ER+/PR-/Unknown

10

13.3

7

70.0

3

30.0

  ER-/unknown/PR+

2

2.7

1

50.0

1

50.0

  ER-/PR-

24

32.0

9

37.5

15

62.5

  Not documented

3

-

HER2 status

.001

  Negative

59

78.7

11

18.6

48

81.4

  Positive

16

21.3

10

62.5

6

37.5

  Not documented

3

-

Drug Therapy

.001

  AC → T

57

71.8

11

19.3

46

80.7

  AC → TH

9

11.5

8

88.9

1

11.1

  TCbH

7

9.0

2

28.6

5

71.4

  AC → TCb

3

3.8

1

33.3

2

66.7

  AC

2

3.6

0

0.0

2

100.0

Treatment adherence

.018

  Yes

60

76.9

21

35.0

39

65.0

  No

18

23.1

1

5.6

17

94.4